To investigate the safety and tolerability after single and multiple ascending doses of MDR-001 Tablets administered orally in healthy participants and obese/ overweight participants.
Participants who are aged ≥ 18 and ≤ 55 years at the time of signing the informed consent; no gender restriction.
Participants with 27 ≤ body mass index (BMI) ≤ 45 kg/m2.
For male participants, a waist circumference ≥ 90 cm is required, while female participants ≥ 85 cm.
Participants with any condition that increases the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers.
Participants with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia 2 (MEN2), or those with hereditary diseases that easily induce to medullary thyroid carcinoma.
Participants with a history of pancreatitis or symptomatic gallbladder disease.
Serum calcitonin > ULN at screening.